Pulse Biosciences (PLSE)
NASDAQ:PLSE
Want to see PLSE full AI Analyst Report?
PLSE Stock Chart & Stats
$23.40
-$0.27(-1.46%)
At close: 4:00 PM EST
$23.40
-$0.27(-1.46%)
Day’s Range― - ―
52-Week Range$12.56 - $27.98
Previous CloseN/A
Volume31.18K
Average Volume (3M)189.63K
Market Cap
$1.79B
Enterprise Value$1.73B
Total Cash (Recent Filing)$68.32M
Total Debt (Recent Filing)$7.16M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Aug 12, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding69,209,710
10 Day Avg. Volume222,519
30 Day Avg. Volume189,626
Financial Highlights & Ratios
PEG Ratio-0.73
Price to Book (P/B)11.47
Price to Sales (P/S)2643.82
P/FCF Ratio-17.00
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue2.30K
Enterprise Value/Gross Profit-2.53K
Enterprise Value/Ebitda-23.46
Forecast
1Y Price Target
$30.00Price Target Upside28.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.18
Revenue Forecast (FY)$3.30M
Bulls Say, Bears Say
Bulls Say
Robust Clinical Efficacy & SafetyLarge European feasibility outcomes across 177 subjects showing high acute and durable success with a low SAE rate provide durable clinical validation. Strong safety/efficacy evidence supports regulatory filings, adoption by electrophysiologists, and reduces clinical execution risk over the next 2–6 months.
Pivotal IDE Launched And Accelerated TimelinesInitiation and tightened timelines for the U.S. pivotal IDE (Bayesian design, up to ~215 patients) materially advances regulatory pathway and shortens time‑to‑market. Faster enrollment and adaptive design reduce regulatory timing uncertainty and strengthen commercialization timing visibility.
Recurring Consumables + Capital Equipment ModelA dual revenue model—console sales plus single‑use disposables—creates an annuity‑like consumable stream as installed base grows. This supports margin sustainability and predictable per‑procedure cash generation as device adoption scales, making long‑term revenue more durable than one‑time sales alone.
Bears Say
Substantial Cash BurnOperating cash outflows vastly exceed cash generation, meaning the company is consuming reserves each quarter. Sustained cash burn creates structural reliance on external financing or rapid commercialization to avoid dilution, constraining strategic optionality over the medium term.
Commercial Immaturity & Negative Gross ProfitRevenue remains nascent versus a cost base that produces negative gross profit and very wide losses. Until product revenue scales and unit economics normalize, margin recovery is uncertain, pressuring the path to self‑funding and long‑term profitability.
Market Adoption And Population Variability RisksBroader adoption risks—historically low concomitant AF uptake and possible differences between European feasibility and U.S. populations (e.g., BMI, mapping integration)—could slow scale. These structural market and transferability risks may delay commercial traction and installed base growth.
Pulse Biosciences News
PLSE FAQ
What was Pulse Biosciences’s price range in the past 12 months?
Pulse Biosciences lowest stock price was $12.56 and its highest was $27.98 in the past 12 months.
What is Pulse Biosciences’s market cap?
Pulse Biosciences’s market cap is $1.79B.
When is Pulse Biosciences’s upcoming earnings report date?
Pulse Biosciences’s upcoming earnings report date is Aug 12, 2026 which is in 77 days.
How were Pulse Biosciences’s earnings last quarter?
Pulse Biosciences released its earnings results on May 04, 2026. The company reported -$0.238 earnings per share for the quarter, beating the consensus estimate of -$0.27 by $0.032.
Is Pulse Biosciences overvalued?
According to Wall Street analysts Pulse Biosciences’s price is currently Undervalued.
Does Pulse Biosciences pay dividends?
Pulse Biosciences does not currently pay dividends.
What is Pulse Biosciences’s EPS estimate?
Pulse Biosciences’s EPS estimate is -0.28.
How many shares outstanding does Pulse Biosciences have?
Pulse Biosciences has 69,209,710 shares outstanding.
What happened to Pulse Biosciences’s price movement after its last earnings report?
Pulse Biosciences reported an EPS of -$0.238 in its last earnings report, beating expectations of -$0.27. Following the earnings report the stock price went down -3.841%.
Which hedge fund is a major shareholder of Pulse Biosciences?
Currently, no hedge funds are holding shares in PLSE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pulse Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$30.00 (28.21% Upside)
$30.00 (28.21% Upside)
Blogger Sentiment
Bullish
PLSE Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 31.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $13.3M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.46%
12-Months-Change
Fundamentals
Return on Equity
-86.67%
Trailing 12-Months
Asset Growth
-38.81%
Trailing 12-Months
Company Description
Pulse Biosciences
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
PLSE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial clinical progress and clear operational momentum: landmark European feasibility results (strong efficacy and low SAE rate), initiation and acceleration of the U.S. pivotal IDE trial, regulatory milestones and expanded clinical programs (surgical clamp and Vybrance). These positive milestones were balanced against near‑term commercial immaturity (very small product revenue), rising R&D/clinical spend driving wider GAAP and non‑GAAP losses, and a material quarterly cash burn that reduced cash balances. Management has strengthened leadership, prioritized the high‑value catheter program and secured financing flexibility (shelf and ATM) to support execution. On balance, the clinical and operational advances meaningfully outweigh the financial and timing challenges reported.View all PLSE earnings summariesPLSE Stock 12 Month Forecast
Average Price Target
$30.00
▲(28.21% Upside)
Technical Analysis
Ownership Overview
73.02% Insiders
2.24% Mutual Funds
1.81% Other Institutional Investors
20.24% Public Companies and
Individual Investors